Pertussis can cause violent and rapid coughing, over and over, until the air is gone from your lungs. When there is no more air in the lungs, you are forced to inhale with a loud “whooping” sound. This extreme coughing can cause you to throw up and be very tired. Although you are often exhausted after a coughing fit, you usually appear fairly well in-between. Coughing fits generally become more common and bad as the illness continues, and can occur more often at night. The coughing fits can go on for up to 10 weeks or more. In China, pertussis is known as the “100 day cough.”
A chronic cough can be due to lung cancer, but may also be related to allergies, recurrent viral infections, or a multitude of other conditions. Both COPD and lung cancer may have similar symptoms. Tuberculosis not only raises the risk of developing lung cancer, but the two are not uncommonly misdiagnosed as the other. Since there is so much overlap between different diagnoses, it's important to talk to your doctor about all of your symptoms, even if any of those symptoms seem mild. The combination of symptoms you experience may be more important than individual symptoms.
A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was months in the nab-paclitaxel-gemcitabine group as compared with months in the gemcitabine group (hazard ratio for death, ; 95% confidence interval [CI], to ; P<). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was months in the nab-paclitaxel-gemcitabine group, as compared with months in the gemcitabine group (hazard ratio for disease progression or death, ; 95% CI, to ; P<); the response rate according to independent review was 23% versus 7% in the two groups (P<). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.